- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06326047
Um estudo de pesquisa comparando quão bem diferentes doses do medicamento NN0519-0130 reduzem o açúcar no sangue em pessoas com diabetes tipo 2
Investigação da segurança e eficácia de NNC0519-0130 uma vez por semana em participantes com diabetes tipo 2 - um estudo para determinação de dose
This study will look at how well a new medicine called NNC0519-0130 helps people with type 2 diabetes lower their blood sugar and body weight. The study will test up to 7 different doses of NNC0519-0130. Which treatment participant will get is decided by chance. Participants will take 1-3 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 40 weeks.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
New South Wales
-
Campbelltown, New South Wales, Austrália, 2560
- Campbelltown Hospital
-
Macquarie Park, New South Wales, Austrália, 2109
- Macquarie University - Clinical Trials Unit
-
St Leonards, New South Wales, Austrália, 2065
- Royal North Shore Hospital
-
Sydney, New South Wales, Austrália, 2148
- Western Endocrine Blacktown
-
Sydney, New South Wales, Austrália, 2148
- Roger Chih Yu Chen
-
Wollongong, New South Wales, Austrália, 2500
- Illawarra Diabetes Service Clinical Trials & Research Unit
-
-
Queensland
-
Birtinya, Queensland, Austrália, 4575
- University of Sunshine Coast - Vitality Village
-
Meadowbrook, Queensland, Austrália, 4131
- Logan Hospital
-
-
South Australia
-
Oaklands Park, South Australia, Austrália, 5046
- Southern Adelaide Diabetes & Endocrine Services
-
-
Victoria
-
Box Hill, Victoria, Austrália, 3128
- Eastern Clinical Research Unit Box Hill
-
Camberwell, Victoria, Austrália, 3124
- Emeritus Research Melbourne
-
Heidelberg Heights, Victoria, Austrália, 3081
- Austin Health, Metabolic Disorders Centre
-
Parkville, Victoria, Austrália, 3050
- The Royal Melbourne Hospital
-
Parkville, Victoria, Austrália, 3050
- The Royal Melbourne Hospital - Diabetes & Endocrinology Department
-
-
Western Australia
-
Fremantle, Western Australia, Austrália, 6160
- Fremantle Hospital
-
-
-
-
-
Québec, Canadá, G1V 4T3
- Diex Recherche Quebec
-
-
British Columbia
-
Kelowna, British Columbia, Canadá, V1Y 1Z9
- OCT Research ULC (dba Okanagan Clinical Trials)
-
Richmond, British Columbia, Canadá, V6V 2L1
- OCT Research ULC (dba Okanagan Clinical Trials)
-
Victoria, British Columbia, Canadá, V8V 4A1
- Cook Street Medical Clinic
-
-
New Brunswick
-
Moncton, New Brunswick, Canadá, E1G 1A7
- G.A. Research Associates Ltd.
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canadá, B3H 1V7
- Nova Scotia Hlth Halifax
-
-
Ontario
-
Barrie, Ontario, Canadá, L4N 7L3
- Centricity Research Barrie
-
Hamilton, Ontario, Canadá, L8L 5G8
- Wharton Medical Clinic Clinical Trials (Hamilton)
-
Sarnia, Ontario, Canadá, N7T 4X3
- London Road Diagnostic Clinic and Medical Centre
-
Toronto, Ontario, Canadá, M4G 3E8
- Centricity Research Toronto
-
Toronto, Ontario, Canadá, M9V 4B4
- Albion Finch Medical Centre
-
-
Quebec
-
Lévis, Quebec, Canadá, G6W 0M5
- Centricity Research Quebec City
-
Mirabel, Quebec, Canadá, J7J 2K8
- Centricity Research Mirabel
-
Montreal, Quebec, Canadá, H1Y 3H5
- Recherche GCP Research
-
Saint-Laurent, Quebec, Canadá, H4T 1Z9
- Centricity Research Ville St. Laurent VSL
-
-
-
-
-
Seoul, Coréia do Sul, 05505
- Asan Medical Center
-
Seoul, Coréia do Sul, 01830
- Nowon Eulji Medical Center, Eulji University
-
Seoul, Coréia do Sul, 03181
- Kangbuk Samsung Hospital
-
Seoul, Coréia do Sul, 02841
- Korea University Anam Hospital
-
-
Gyeonggi-do
-
Seongnam-si, Gyeonggi-do, Coréia do Sul, 13620
- Seoul National University Bundang Hospital
-
-
-
-
California
-
Chula Vista, California, Estados Unidos, 91911
- Velocity Clin Res-Chula Vista
-
Fresno, California, Estados Unidos, 93720
- Valley Research
-
Inglewood, California, Estados Unidos, 90301
- 310 Clinical Research
-
La Mesa, California, Estados Unidos, 91942
- Velocity Clin Res San Diego
-
Lancaster, California, Estados Unidos, 93534
- First Valley Med Grp Lancaster
-
Lomita, California, Estados Unidos, 90717
- Torrance Clin Res Inst, Inc.
-
Los Alamitos, California, Estados Unidos, 90720
- Pacific Clinical Studies
-
Los Angeles, California, Estados Unidos, 90057
- Velocity Clinical Research Westlake
-
Montclair, California, Estados Unidos, 91763
- Catalina Research Institute, LLC
-
San Diego, California, Estados Unidos, 92123
- Artemis Insitute for Clin Res
-
Toluca Lake, California, Estados Unidos, 91602
- Med Partners, Inc.
-
Torrance, California, Estados Unidos, 90505
- UCLA Health Southbay Endocrine
-
Tustin, California, Estados Unidos, 92780
- University Clin Investigators
-
Walnut Creek, California, Estados Unidos, 94598
- Diablo Clinical Research, Inc.
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- University of Colorado Hospital
-
-
Florida
-
Clearwater, Florida, Estados Unidos, 33756
- Innovative Research of W Florida Inc.
-
Clearwater, Florida, Estados Unidos, 33756
- Innovative Research of W FL
-
Miami, Florida, Estados Unidos, 33183
- International Research Associates, LLC_Miami
-
-
Georgia
-
Columbus, Georgia, Estados Unidos, 31904
- Centricity Research
-
-
Idaho
-
Blackfoot, Idaho, Estados Unidos, 83221
- Elite Clinical Trials
-
-
Illinois
-
Peoria, Illinois, Estados Unidos, 61603
- Methodist Medical Center of Illinois
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52242
- University of Iowa
-
-
Maryland
-
Columbia, Maryland, Estados Unidos, 21045
- Centennial Medical Group
-
Oxon Hill, Maryland, Estados Unidos, 20745
- MD Medical Research
-
Rockville, Maryland, Estados Unidos, 20852
- Endo And Metab Cons
-
-
Missouri
-
Springfield, Missouri, Estados Unidos, 65807
- Clinvest Research
-
-
Montana
-
Butte, Montana, Estados Unidos, 59701
- Mercury Str Med Grp, PLLC
-
-
Nebraska
-
Lincoln, Nebraska, Estados Unidos, 68510
- Velocity Clinical Research Lincoln
-
-
Nevada
-
Las Vegas, Nevada, Estados Unidos, 89148
- Palm Research Center Inc-Vegas
-
Las Vegas, Nevada, Estados Unidos, 89109
- Excel Clinical Network
-
-
New York
-
Binghamton, New York, Estados Unidos, 13905
- Velocity Clinical Research Binghamton
-
-
North Carolina
-
Greensboro, North Carolina, Estados Unidos, 27408
- PharmQuest Life Sciences LLC
-
Wilmington, North Carolina, Estados Unidos, 28401
- Accellacare Wilmington
-
-
Ohio
-
Canton, Ohio, Estados Unidos, 44718
- Diab & Endo Assoc of Stark Co
-
Cincinnati, Ohio, Estados Unidos, 45242
- Velocity Clin Res_Cincinnati
-
Cincinnati, Ohio, Estados Unidos, 45246
- Velocity Clinical Research Springdale
-
Dayton, Ohio, Estados Unidos, 45439
- Providence Health Partners Ctr
-
Maumee, Ohio, Estados Unidos, 43537
- Advanced Med Res Maumee
-
-
Oregon
-
Grants Pass, Oregon, Estados Unidos, 97527
- Velocity Clin Res Grants Pass
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19114
- Tristar Clin Investigations, PC
-
Pittsburgh, Pennsylvania, Estados Unidos, 15243
- Preferred Primary Care Physicians Inc.
-
Uniontown, Pennsylvania, Estados Unidos, 15401
- Preferred Primary Care Physicians, Inc.
-
-
Texas
-
Abilene, Texas, Estados Unidos, 79606
- Velocity Clinical Research Abilene
-
Austin, Texas, Estados Unidos, 78759
- Velocity Clin Res Austin
-
Dallas, Texas, Estados Unidos, 75390
- UT Southwestern Med Center
-
Dallas, Texas, Estados Unidos, 75230
- Velocity Clinical Res-Dallas
-
Dallas, Texas, Estados Unidos, 75230
- Zenos Clinical research
-
Forney, Texas, Estados Unidos, 75126
- Care United Research, LLC
-
Houston, Texas, Estados Unidos, 77004
- Endocrine Associates Houston
-
Houston, Texas, Estados Unidos, 77043
- Biopharma Informatic_Houston
-
Irving, Texas, Estados Unidos, 75039
- Tekton Research
-
Lewisville, Texas, Estados Unidos, 75057
- Epic Clinical Research
-
Shavano Park, Texas, Estados Unidos, 78231
- Consano Clinical Research, LLC
-
-
Virginia
-
Burke, Virginia, Estados Unidos, 22015
- Burke Internal Medicine & Research
-
Newport News, Virginia, Estados Unidos, 23606
- TPMG Clinical Research
-
-
-
-
-
Chiba, Japão, 261-0004
- Tokuyama clinic_Diabetic internal medicine
-
Soka-shi, Saitama, Japão, 340-0015
- Soka Sugiura Internal Medicine Clinic
-
Tokyo, Japão, 104-0031
- Fukuwa Clinic
-
Tokyo, Japão, 103-0027
- Tokyo-Eki Center-building Clinic_Internal Medicine
-
Tokyo, Japão, 104-0031
- Fukuwa Clinic_Internal Medicine
-
-
-
-
Free State
-
Bloemfontein, Free State, África do Sul, 9301
- Josha Research
-
-
Gauteng
-
Johannesburg, Gauteng, África do Sul, 2013
- Wits Bara Clinical Trial Site
-
Midrand, Gauteng, África do Sul, 1685
- Dr A Jacovides and Partners Inc
-
-
KwaZulu-Natal
-
Durban, KwaZulu-Natal, África do Sul, 4450
- Dr Pillay's Rooms
-
eMkhomazi, KwaZulu-Natal, África do Sul, 4170
- Dr T Padayachee
-
-
-
-
-
Bengaluru, Índia, 560054
- MS Ramaiah
-
New Delhi, Índia, 110001
- Lady Hardinge Medical College
-
-
Karnataka
-
Bangalore, Karnataka, Índia, 560092
- Life Care Hospital and Research Centre
-
-
Kerala
-
Kochi, Kerala, Índia, 682041
- Amrita Institute Of Medical Sciences & Research Centre
-
-
Madhya Pradesh
-
Indore, Madhya Pradesh, Índia, 452010
- TOTALL Diabetes Hormone Institute
-
-
Maharashtra
-
Mumbai, Maharashtra, Índia, 400012
- Seth GS Medical College & KEM Hospital
-
Pune, Maharashtra, Índia, 411021
- Chellaram Diabetes Institute
-
-
Rajasthan
-
Jaipur, Rajasthan, Índia, 302006
- Diabetes, Thyroid and Endocrine Centre
-
-
Tamil Nadu
-
Vellore, Tamil Nadu, Índia, 632004
- Christian Medical College Hospital, Vellore
-
-
Telangana
-
Hyderabad, Telangana, Índia, 500082
- Diabetes Research Center, Hyderabad
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Female of non-childbearing potential, or male.
- For United States (US) only: Female of childbearing potential using highly effective non-systemic methods of contraception with low user-dependency and willingness to continue using it through-out the study or male.
- Age 18-75 years (both inclusive) at the time of signing the informed consent.
- Diagnosed with type 2 diabetes mellitus greater than or equal 180 days before screening.
- Stable daily dose(s) more than or equal 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metformin with or without sodium-glucose co-transporter 2 (SGLT2) inhibitor.
- Glycated haemoglobin (HbA1c) of 7.5-10.0% (58-86 millimoles per moles (mmol/mol)) (both inclusive) as assessed by central laboratory at screening.
- Body mass index (BMI) greater than or equal 23.0 kilograms per meter square (kg/m^2).
Exclusion Criteria:
- Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
- Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Dosing scheme A (NNC0519-0130)
Participants will receive NNC0519-0130 at 3 dose levels once weekly (QW) as subcutaneous (s.c.) injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Comparador de Placebo: Dosing scheme A (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Experimental: Dosing scheme B (NNC0519-0130)
Participants will receive NNC0519-0130 at 3 dose levels once weekly (QW) as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Comparador de Placebo: Dosing scheme B (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Experimental: Dosing scheme C (NNC0519-0130)
Participants will receive NNC0519-0130 at 5 dose levels once weekly as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Comparador de Placebo: Dosing scheme C (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Experimental: Dosing scheme D (NNC0519-0130)
Participants will receive NNC0519-0130 at 5 dose levels once weekly as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Comparador de Placebo: Dosing scheme D (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Experimental: Dosing scheme E (NNC0519-0130)
Participants will receive NNC0519-0130 at 7 dose levels once weekly as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Comparador de Placebo: Dosing scheme E (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Comparador Ativo: Dosing scheme F (tirzepatide)
Participants will receive tirzepatide at 6 dose levels once weekly as s.c. injection in dose escalating manner. |
Trizepatide will be administered subcutaneously. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Glycated haemoglobin (HbA1c)
Prazo: From baseline (week 0) to 12 weeks on a given maintenance dose
|
Measured as percentage point (%-point) |
From baseline (week 0) to 12 weeks on a given maintenance dose
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Glycated haemoglobin (HbA1c)
Prazo: From baseline (week 0) to end of treatment (week 36)
|
Measured as percentage point (%-point) |
From baseline (week 0) to end of treatment (week 36)
|
|
Relative change in body weight
Prazo: From baseline (week 0) to end of treatment (week 36)
|
Measured as percentage (%) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in body weight
Prazo: From baseline (week 0) to end of treatment (week 36)
|
Measured as kilograms (kg) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in fasting plasma glucose (FPG)
Prazo: From baseline (week 0) to 12 weeks on a given maintenance dose
|
Measured as millimoles per liter (mmol/L) |
From baseline (week 0) to 12 weeks on a given maintenance dose
|
|
Continuous glucose monitoring (CGM): Change in time in range (TIR) 3.9-10.0 millimoles per liter (mmol/L) (70-180 milligrams per deciliter (mg/dL))
Prazo: From baseline (week -2 to week 0) to week 22-24 and week 34-36, respectively
|
Measured as percentage point (%-point) |
From baseline (week -2 to week 0) to week 22-24 and week 34-36, respectively
|
|
Change in waist circumference
Prazo: From baseline (week 0) to end of treatment (week 36)
|
Measured as centimeter (cm) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in systolic blood pressure (SBP)
Prazo: From baseline (week 0) to end of treatment (week 36)
|
Measured as millimeters of mercury (mmHg) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in high sensitivity C-Reactive Protein (hsCRP)
Prazo: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in total cholesterol
Prazo: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in high-density lipoprotein (HDL) cholesterol
Prazo: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in low-density lipoprotein (LDL) cholesterol
Prazo: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in triglycerides
Prazo: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Number of adverse events
Prazo: From baseline (week 0) to end of study (week 40)
|
Measured as number of events |
From baseline (week 0) to end of study (week 40)
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- NN9541-4945
- U1111-1291-9196 (Outro identificador: World Health Organization (WHO))
- jRCT2031230704 (Identificador de registro: JRCT)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .